Related Experiment Video
Updated: Jul 31, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Characterization of PMP22 expression in osteosarcoma
Maaike van Dartel1, Theo J M Hulsebos
1Department of Human Genetics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Abstract:
The peripheral myelin protein (PMP22) gene is highly expressed in peripheral Schwann cells and encodes an important constituent of the myelin sheath. It is also expressed at lower levels in other normal tissues in which the protein is supposed to be involved in cell growth regulation. We recently reported frequent amplification and overexpression of PMP22 in high-grade osteosarcoma. Here, we analyzed PMP22 expression in five osteosarcoma tumors and three osteosarcoma cell lines. In normal Schwann cells, transcription of PMP22 starts at three promoters, P1A, P1B, and P2, which results in the synthesis of three alternatively spliced transcripts that all code for the same protein. We found a comparable expression pattern in normal osteoblasts. However, promoter P1A-driven transcripts were absent in all investigated tumors and cell lines and, compared to normal osteoblasts, the P1B/P2 transcript ratio was found to be increased in two of three cases with PMP22 overexpression and decreased in all five cases without overexpression. In normal Schwann cells and in NIH3T3 cells, PMP22 expression increases upon serum starvation-induced growth arrest. In contrast to this, serum withdrawal caused a considerable decrease of PMP22 expression in the osteosarcoma cell lines. We conclude that the different PMP22 expression in osteosarcoma may result in alternative availability of the PMP22 protein during the cell cycle and aberrant regulation of cell growth control in osteosarcoma tumorigenesis.
Insights
Peripheral myelin protein (PMP22) gene alterations in osteosarcoma disrupt normal cell growth regulation. Aberrant PMP22 expression patterns were observed in tumors and cell lines, impacting tumorigenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Peripheral myelin protein (PMP22) is crucial for myelin sheath formation and involved in cell growth regulation in normal tissues.
- PMP22 gene amplification and overexpression have been previously linked to high-grade osteosarcoma.
- Understanding PMP22 expression patterns is vital for elucidating osteosarcoma development.
Purpose of the Study:
- To analyze PMP22 gene expression patterns in osteosarcoma tumors and cell lines.
- To investigate the role of PMP22 promoters (P1A, P1B, P2) in osteosarcoma.
- To compare PMP22 regulation in osteosarcoma cells versus normal cells under growth arrest conditions.
Main Methods:
- Analysis of PMP22 expression in five osteosarcoma tumors and three cell lines.
- Examination of PMP22 promoter-specific transcripts (P1A, P1B, P2).
- Assessment of PMP22 expression changes in response to serum withdrawal in osteosarcoma and normal cell lines.
Main Results:
- Promoter P1A-driven PMP22 transcripts were absent in all osteosarcoma samples.
- The P1B/P2 transcript ratio was altered in osteosarcoma compared to normal osteoblasts.
- Serum withdrawal decreased PMP22 expression in osteosarcoma cell lines, unlike in normal cells.
Conclusions:
- Altered PMP22 expression, particularly the absence of P1A transcripts, is characteristic of osteosarcoma.
- Aberrant PMP22 regulation may contribute to uncontrolled cell growth in osteosarcoma.
- PMP22's role in cell cycle regulation is dysregulated in osteosarcoma tumorigenesis.

